Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.034696%Not Available
Abdominal distension07.01.04.0010.008125%
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.029464%
Acute hepatic failure09.01.03.0010.000964%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.001447%Not Available
Acute psychosis19.03.01.0010.000241%Not Available
Acute pulmonary oedema02.05.02.004; 22.01.03.0050.000362%Not Available
Acute respiratory failure22.02.06.001; 14.01.04.0040.004629%Not Available
Adenocarcinoma16.16.01.0040.000241%Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.0010.000241%
Ageusia17.02.07.001; 07.14.03.0030.008294%Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Amnesia19.20.01.001; 17.03.02.0010.003255%
Anal fistula07.11.05.0020.000241%
Aneurysm24.02.01.0010.000241%Not Available
Angioedema23.04.01.001; 22.04.02.008; 10.01.05.009--Not Available
Anosmia22.04.03.006; 17.04.04.0010.000940%
Aortic stenosis24.04.01.0010.000530%Not Available
Aortic valve incompetence02.07.03.0010.000530%Not Available
Apathy19.04.04.0020.000940%Not Available
Arrhythmia02.03.02.001--Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.000723%Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.003--Not Available
Aspartate aminotransferase increased13.03.04.011--
Aspiration22.02.07.0070.000892%
Asthenia08.01.01.0010.033105%Not Available
Atrial fibrillation02.03.03.0020.004436%
The 1th Page    1 2 3 4 5    Next   Last    Total 12 Pages